Cite

HARVARD Citation

    Brose, M. et al. (n.d.). Vemurafenib for BRAFV600E-positive metastatic papillary thyroid cancer – Authors' response. Lancet oncology. 17 (11), pp. e469-. [Online]. 
  
Back to record